BRANCHINI, Alessio
 Distribuzione geografica
Continente #
NA - Nord America 4.713
EU - Europa 2.131
AS - Asia 1.003
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 9
OC - Oceania 7
SA - Sud America 5
Totale 7.878
Nazione #
US - Stati Uniti d'America 4.702
IT - Italia 1.102
CN - Cina 540
PL - Polonia 255
DE - Germania 195
UA - Ucraina 190
TR - Turchia 161
SG - Singapore 135
GB - Regno Unito 109
SE - Svezia 84
FI - Finlandia 55
ID - Indonesia 45
BE - Belgio 27
CZ - Repubblica Ceca 25
VN - Vietnam 24
HK - Hong Kong 22
IN - India 18
IR - Iran 16
FR - Francia 15
RO - Romania 15
DK - Danimarca 14
NL - Olanda 12
NO - Norvegia 12
JP - Giappone 11
CA - Canada 10
EU - Europa 10
TW - Taiwan 10
AU - Australia 7
BR - Brasile 5
CH - Svizzera 5
KR - Corea 5
PT - Portogallo 4
ET - Etiopia 3
GE - Georgia 3
IE - Irlanda 3
IQ - Iraq 3
NG - Nigeria 3
PK - Pakistan 3
RU - Federazione Russa 3
AT - Austria 2
ES - Italia 2
GR - Grecia 2
IL - Israele 2
KE - Kenya 2
MY - Malesia 2
PH - Filippine 2
MX - Messico 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 7.878
Città #
Chandler 570
Fairfield 504
Woodbridge 441
Ferrara 314
Ann Arbor 277
Ashburn 266
Houston 264
Warsaw 254
Wilmington 220
Jacksonville 215
Seattle 206
Cambridge 173
New York 125
Izmir 119
Princeton 118
Nanjing 99
Dearborn 88
Shanghai 87
Milan 85
Singapore 78
Beijing 73
Bremen 62
Boardman 59
San Diego 45
Jakarta 43
Redwood City 41
Falls Church 35
Nanchang 35
Rome 33
Shenyang 32
Bologna 31
Los Angeles 25
Dong Ket 23
Brussels 22
Guangzhou 21
Hebei 21
Jiaxing 21
Auburn Hills 20
San Mateo 20
Florence 19
Brno 17
Jinan 17
Kunming 16
Changsha 15
Norwalk 15
Helsinki 14
London 14
Tianjin 14
Zhengzhou 13
Washington 12
Hong Kong 11
Mountain View 11
Hangzhou 10
Ningbo 10
Praia A Mare 10
Monmouth Junction 9
Piemonte 9
Augusta 8
Des Moines 8
Duncan 8
Ferrara di Monte Baldo 8
Hefei 8
Oslo 8
Bari 7
Hounslow 7
Toronto 7
Verona 7
Andover 6
Arona 6
Chicago 6
Leawood 6
Orange 6
Redmond 6
Albissola Marina 5
Catania 5
Haikou 5
Olomouc 5
Rochester 5
Taipei 5
Addison 4
Amsterdam 4
Atlanta 4
Bangalore 4
Cagliari 4
Calderara di Reno 4
Calvisano 4
Castelcovati 4
Civitanova Marche 4
Copenhagen 4
Dallas 4
Fuzhou 4
Gragnano 4
Louvain 4
Munich 4
Quartu Sant'elena 4
Ravenna 4
Sala 4
Salerno 4
Terranova 4
Amstelveen 3
Totale 5.626
Nome #
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 258
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 257
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 217
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 193
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 178
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 159
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 154
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 146
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 145
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 140
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 136
Hard surface biocontrol in hospitals using microbial-based cleaning products 135
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 133
Chronic sleep deprivation markedly reduces coagulation factor VII expression 130
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 122
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 119
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 119
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 116
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 115
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 115
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 115
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 106
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 100
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 100
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 100
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 98
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 98
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 98
F9 genotype and PK hemophilia B international study (GEPKHIS) 95
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 95
null 94
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 93
null 93
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 90
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 90
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 89
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 87
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 84
null 84
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 76
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 74
null 73
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 73
null 71
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 71
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 71
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 70
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 68
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 64
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 63
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 62
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 62
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 60
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 60
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 57
The carboxyl-terminal region of coagulation serine proteases: A matter of cut and change 57
null 56
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 56
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 55
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 53
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 53
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 52
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 52
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 51
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 50
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 49
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 48
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 47
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 46
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 46
null 45
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 45
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 45
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 45
null 44
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 43
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 43
Next generation factor VIIa with enhanced half-life 43
Hemostasis gene expression of the internal jugular and saphenous veins 43
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 41
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 41
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 40
Improved intracellular processing of protein variants as a personalised therapeutic approach for haemophilia 39
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 39
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 39
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 38
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 38
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 37
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 35
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 35
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 34
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 31
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 31
Academic Editor per la rivista PLoS One 31
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 31
Caratterizzazione dei determinanti molecolari del processo di soppressione di mutazioni nonsenso mediato da ribosome readthrough 30
Translation termination codons in protein synthesis and disease 29
Exploring base editing for the correction of nonsense mutations in hemophilia B 29
Associate Editor per la rivista Frontiers in Genetics - sezione Genetic Disorders 29
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 28
Totale 7.863
Categoria #
all - tutte 37.398
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 166
Totale 37.564


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.512 240 61 53 185 122 242 151 126 123 125 55 29
2020/20211.400 64 55 53 92 61 100 255 176 82 198 179 85
2021/20221.181 170 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/202581 81 0 0 0 0 0 0 0 0 0 0 0
Totale 8.220